ReviewClinical & developmental immunology2012
Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 116 citations in OpenAlex.
- Pulmonary arterial flow alterations in systemic lupus erythematosus on 4D flow CMR: a case-control study.European radiology experimental · 2026Article
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects.Biomolecules · 2026Review
- Research advances in connective tissue disease-associated pulmonary arterial hypertension with an emphasis on the Chinese population.Frontiers in medicine · 2026Review
- Hydroxychloroquine withdrawal triggers pregnancy-associated pulmonary arterial hypertension in systemic lupus erythematosus: a case report and exploration of the Complement-EndMT axis.Frontiers in pharmacology · 2026Article
- Pulmonary Hypertension in Systemic Lupus Erythematosus: Current Evidence and Future Directions.Cureus · 2025Review
- Exercise Right Heart Catheterization: The Key to Unraveling the Mystery of Recurrent Syncope.JACC. Case reports · 2025Article
- Severe pulmonary arterial hypertension development despite lupus nephritis remission: association with podocytic infolding glomerulopathy.BMC nephrology · 2025Article
- Pulmonary Involvement in Systemic Lupus Erythematosus: A Potentially Overlooked Condition.Biomedicines · 2025Review
- Pulmonary arterial hypertension in systemic lupus erythematosus: identification of risk factors and haemodynamics characteristics in a multicentre retrospective cohort.Lupus science & medicine · 2025Article
- Prevalence, molecular mechanisms and diagnostic approaches to pulmonary arterial hypertension in connective tissue diseases.Rheumatology international · 2025Review
- High Prevalence of Myositis-Specific and Associated Antibodies in Patients with Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2024Article
- Recent developments in connective tissue disease associated pulmonary arterial hypertension.International journal of cardiology. Congenital heart disease · 2024Review
- Article
- Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert Consensus.ACR open rheumatology · 2023Article
- Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.Clinical rheumatology · 2023Review
- A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.Respiratory research · 2023Article
- Refractory systemic lupus erythematosus with chylous effusion successfully treated with sirolimus: a case report and literature review.Rheumatology international · 2023Review
- Fenestration: Integrating Wings Into the Atrial Septal Occluder for Navigating a Challenging Terrain.Cureus · 2023Article
- Article
- Systemic Lupus Erythematosus and Pulmonary Hypertension.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The pathophysiology of PAH involves multiple mechanisms from vasculitis and in-situ thrombosis to interstitial pulmonary fibrosis which increases pulmonary vascular resistance, potentially leading to right heart failure. Immune and inflammatory mechanisms may play a significant role in the pathogenesis or progression of PAH in patients with CTDs, establishing a role for anti-inflammatory and immunosuppressive therapies. The leading predictors of PAH in SLE are Raynaud phenomenon, anti-U1RNP antibody, and anticardiolipin antibody positivity. The first-line of diagnostic testing for patients with suspected SLE-associated PAH (SLE-aPAH) involves obtaining a Doppler echocardiogram. Once the diagnosis is confirmed by right heart catheterization, SLE-aPAH patients are generally treated with oxygen, anticoagulants, and vasodilators. Although the prognosis and therapeutic responsiveness of these patients have improved with the addition of intensive immunosuppressive therapies, these treatments are still largely unproven. Recent data put the one-year survival rate for SLE-aPAH patients at 94%. Pregnant women are most at risk of dying due to undiagnosed SLE-aPAH, and screening should be considered essential in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.